Industry Portals
Biotechnical Industry News
Integer a velit nec risus malesuada imperdiet id et odio. Nunc sit amet mauris dapibus, feugiat diam eget, suscipit, nam gravida nulla eget turpis commodo.
Young & Partners 2023 Chemical Conference: Kamal Nanavaty: Perspectives on the Asian Chemical Industry and Markets
Kamal Nanavaty, President, Strategy Development, Reliance Industries Limited
Young & Partners 2023 Chemical Conference: Matthias Zachert Fireside Chat: Chemical Industry in Europe – Quo Vadis
Matthias Zachert, Chairman of the Management Board, CEO, Lanxess AG
Young & Partners 2023 Pharmaceutical Executive Summit: Speakers Roundtable- What Does the Future Hold
Doug Long, Vice President, Industry Relations, IQVIA Peter Stein, M.D., Director, Office of New Drugs, U.S. Food and Drug Administration Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners; former Deputy Commissioner for Medical Products and Tobacco, U.S. Food and Drug Administration Eli Weinberg, Partner, Bain & Company Life Sciences
Young & Partners 2023 Pharmaceutical Executive Summit: Disruptive Innovation, Research, Manufacturing and AI
Dr. Stephen P. Spielberg, M.D. PhD, Senior Adviser, Young & Partners; former Deputy Commissioner for Medical Products and Tobacco, FDA Eli Weinberg, Partner, Bain & Company Life Sciences.
Young & Partners 2023 Pharmaceutical Executive Summit: Doug Long: The Pharmaceutical Market: Trends, Issues and Outlook
Doug Long, Vice President, IQVIA Holdings Inc.
Young & Partners 2023 Pharmaceutical Executive Summit: Peter Stein Fireside Chat: Brave New World- Adapting to Change
Dr. Peter Stein, Director, Office of New Drugs, U.S. Food and Drug Administration
Young & Partners Forum: A Look Into the Future (October 17, 2023)
Robert Westervelt, Editor in Chief, Chemical Week Peter Young, CEO and Managing Partner, Young & Partners
Biopharma Market Review and Outlook (Pharmaceutical Executive, October 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in the first half, and the outlook for 2023.
Young & Partners Forum: The Impact of AI on the Life Sciences Industry (September 18, 2023)
Panelists: Dylan Reid, Partner, Zetta Ventures Eli Weinberg, Life Sciences Partner, Bain & Company Moderator: Peter Young, CEO and Managing Partner, Young & Partners
Chem Financing to Remain Challenged (ICIS Chemical Business August 18 – August 24, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Financings and the outlook for 2023.
Chemical M&A Activity Turns Up (ICIS Chemical Business August 11 – August 17, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2023.
Young & Partners Biotech Financing Review and Outlook (June 21, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (June 5, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Pharma M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Biotech M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)
Young & Partners shares analysis of the global disruptions and uncertainties that have affected Biopharma M&A and the outlook for 2023.
Debt Financing to be difficult in 2023 (ICIS Chemical Business February 3 – February 9, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Stock Prices and Financings and the outlook for 2023.
Young & Partners Pharma and Biotech M&A Review and Outlook (January 20, 2023)
Proprietary data and analysis of 2022 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (January 17, 2023)
Proprietary data and analysis of 2022 and the current outlook.